Deparment of Surgery, Campus Charité Mitte and Campus Virchow-Klinikum, Charité-Universitätsmedizin Berlin, 13353 Berlin, Germany.
BIH Charité (Digital) Clinician Scientist Program, Berlin Institute of Health, 10178 Berlin, Germany.
Medicina (Kaunas). 2021 Aug 12;57(8):819. doi: 10.3390/medicina57080819.
: In children, hepatoblastoma preferentially is managed by liver resection (LR). However, in irresectable cases, liver transplantation (LT) is required. The aim of our study was to compare short- and long-term results after LR and LT for the curative treatment of hepatoblastoma. : Retrospective analysis of all patients treated surgically for hepatoblastoma from January 2000 until December 2019 was performed. Demographic and clinical data were collected before and after surgery. The primary endpoints were disease free survival and patient survival. : In total, 38 patients were included into our analysis ( = 28 for LR, = 10 for LT) with a median follow-up of 5 years. 36 patients received chemotherapy prior to surgery. Total hospital stay and intensive care unit (ICU) stay were significantly longer within the LT vs. the LR group (ICU 23 vs. 4 days, hospital stay 34 vs. 16 days, respectively; < 0.001). Surgical complications (≤Clavien-Dindo 3a) were equally distributed in both groups (60% vs. 57%; = 1.00). Severe complications (≥Clavien-Dindo 3a) were more frequent after LT (50% vs. 21.4%; = 0.11). Recurrence rates were 10.7% for LR and 0% for LT at 5 years after resection or transplantation ( = 0.94). Overall, 5-year survival was 90% for LT and 96% for LR ( = 0.44). : In irresectable cases, liver transplantation reveals excellent outcomes in children with hepatoblastoma with an acceptable number of perioperative complications.
儿童肝母细胞瘤首选肝切除术(LR)治疗。然而,在不可切除的情况下,需要进行肝移植(LT)。我们的研究旨在比较 LR 和 LT 治疗肝母细胞瘤的短期和长期结果。
回顾性分析了 2000 年 1 月至 2019 年 12 月期间接受手术治疗的所有肝母细胞瘤患者。收集了手术前后的人口统计学和临床数据。主要终点是无病生存率和患者生存率。
共纳入 38 例患者(LR 组 28 例,LT 组 10 例),中位随访时间为 5 年。36 例患者在手术前接受了化疗。LT 组的总住院时间和重症监护病房(ICU)停留时间明显长于 LR 组(ICU 23 天 vs. 4 天,住院时间 34 天 vs. 16 天; < 0.001)。两组的手术并发症(≤Clavien-Dindo 3a)发生率相当(60% vs. 57%; = 1.00)。LT 后严重并发症(≥Clavien-Dindo 3a)更为常见(50% vs. 21.4%; = 0.11)。LR 组和 LT 组的 5 年复发率分别为 10.7%和 0%( = 0.94)。总体而言,LT 的 5 年生存率为 90%,LR 的 5 年生存率为 96%( = 0.44)。
在不可切除的情况下,肝移植为患有肝母细胞瘤的儿童提供了出色的结果,并且围手术期并发症的数量可以接受。